Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | STAT3 | P40763 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 5/20 | 0.49 |
| ▸ | RAB9A | P51151 | 5/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.47 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8185767 | 0.88 | MEN1 (0.46) | ATMMEN1KMT2ASTAT3NPC1 | |
| SCHEMBL5598135 | 0.84 | STAT3 (0.47) | ATMMEN1KMT2ASTAT3NPC1 | |
| SCHEMBL20320379 | 0.82 | ATM (0.55) | ATMMEN1KMT2ASTAT3NPC1 | |
| SCHEMBL15729859 | 0.82 | NPC1 (0.57) | ATMMEN1KMT2ANPC1RAB9A | |
| SCHEMBL5597897 | 0.81 | PTGS1 (0.50) | ATMMEN1KMT2ASTAT3NPC1 | |
| SCHEMBL5650521 | 0.81 | MEN1 (0.57) | ATMMEN1KMT2ANPC1RAB9A | |
| SCHEMBL17295319 | 0.81 | MEN1 (0.50) | ATMMEN1KMT2ANPC1RAB9A | |
| SCHEMBL17290757 | 0.81 | MEN1 (0.50) | ATMMEN1KMT2ANPC1RAB9A | |
| SCHEMBL21121310 | 0.81 | HRH3 (0.58) | MAPT | |
| SCHEMBL5214995 | 0.79 | PTGS2 (0.67) | ATMMEN1KMT2APTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040248950-A1 | Apo ai expression accelerating agent | SHIONOGI & CO., LTD. (JP) | 2004-12-09 | — | — | US | disclosed |
| EP-1419770-A1 | APO AI EXPRESSION ACCELERATING AGENT | SHIONOGI & CO., LTD. (JP) | 2004-05-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248950-A1 | Apo ai expression accelerating agent | APOB, APOL1, NR1H2 | ATM 3513/4885MEN1 4169/4885KMT2A 2520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.